Blackfynn Builds Therapeutic Pipeline with Option to a Phase 3-Ready Drug for Parkinson’s
PHILADELPHIA, Feb. 18, 2021 /PRNewswire/ -- Blackfynn, a company using a systematic approach that combines data, technology and disease-specific clinical expertise...